|
|
||||||||

1From the Ocular Surface Center, Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas; 2Allergan Inc., Irvine, California; and the 3Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas.
PURPOSE. To investigate the role of interferon (IFN)-
in the pathogenesis of conjunctival squamous metaplasia in dry eye.
METHODS. Experimental dry eye was created by subjecting C57BL/6 and IFN-
-knockout mice to desiccating environmental stress for 5 or 10 days. T-cell antigens and IFN-
were detected by immunohistochemistry. Goblet cells were counted in periodic acid Schiff (PAS)stained sections. Expression of small, proline-rich protein (SPRR)-2 was evaluated by confocal microscopy. Tear IFN-
was measured by immunobead assay.
RESULTS. Dry eye promoted migration of CD4+T cells and IFN-
+ cells into goblet cell zones of the conjunctiva and increased the concentration of IFN-
in tears. This migration was accompanied by progressive goblet cell loss and an increase in SPRR-2 expression in the conjunctival epithelium. A significant inverse correlation was observed between the density of infiltrating CD4+T cells and goblet cells. Dry eye had no effect on conjunctival goblet cell density in IFN-
-knockout mice; however, exogenous administration of IFN-
significantly decreased goblet cell density after 5 days.
CONCLUSIONS. Conjunctival epithelial response to experimental dryness is related to the degree of CD4+T-cell infiltration and the level of IFN-
production. These findings suggest that IFN-
plays a pivotal role in promoting conjunctival squamous metaplasia in dry eye, and they provide insight into the immune pathogenesis of keratoconjunctivitis sicca.
This article has been cited by other articles:
![]() |
S. Li, K. Nikulina, J. DeVoss, A. J. Wu, E. C. Strauss, M. S. Anderson, and N. A. McNamara Small Proline-Rich Protein 1B (SPRR1B) Is a Biomarker for Squamous Metaplasia in Dry Eye Disease Invest. Ophthalmol. Vis. Sci., January 1, 2008; 49(1): 34 - 41. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |